Jack Phillips - 04 Apr 2025 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role
Chief Executive Officer, Director
Signature
/s/ David Patience, attorney-in-fact
Issuer symbol
AXDX
Transactions as of
04 Apr 2025
Transactions value $
-$16,473
Form type
4
Filing time
07 Apr 2025, 19:34:08 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXDX Common Stock Options Exercise $0 +53.3K +32.6% $0.00 217K 04 Apr 2025 Direct F1
transaction AXDX Common Stock Sale -$16.5K -25.3K -11.69% $0.65 191K 04 Apr 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXDX Employee Restricted Stock Units Options Exercise $0 -53.3K -100% $0.00 0 04 Apr 2025 Common Stock 53.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F2 The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F3 On April 4, 2022, the reporting person was granted a total of 88,806 RSUs, of which 40% vest on April 4, 2024 and the remaining 60% vest on April 4, 2025.